Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 16/20 | 0.42 |
| ▸ | AURKA | O14965 | 14/20 | 0.42 |
| ▸ | LCK | P06239 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12404579 | 0.82 | AURKA (0.54) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14534233 | 0.80 | AURKB (0.45) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14533906 | 0.72 | AURKA (0.51) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899597 | 0.71 | AURKA (0.43) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14533851 | 0.69 | AURKB (0.47) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14538362 | 0.65 | LCK (0.46) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14537074 | 0.64 | LCK (0.49) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL12473195 | 0.63 | CHEK1 (0.53) | AURKBAURKALCKCHEK1KDR | |
| SCHEMBL12404465 | 0.62 | AURKA (0.67) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL8429700 | 0.62 | AURKA (0.63) | AURKBAURKACHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKB 24/4885AURKA 5/4885LCK 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.